This stock continued to linger since it nice rise to 64 cents last year. Need a little positive news such as large sale of units , approved code and cash infusion to avoid dilution . I keep reviewing the stock and just see growth around the corner. We are through most of the trials , we have our FDA approval and we are already placing devices in several states. We are so far ahead of all the other overpriced otcb bio stocks that trade far higher than us yet are still in phase 2 and trade on hope. We are well past the hope guideline and I anticipate 50 cents by next earnings and then over one buck by years end .
News 
Market Data 
Discover 
